Adenovirus-expressed preS2 antibody inhibits hepatitis B virus infection and hepatic carcinogenesis

Figure 1 Expression and identification of the Ad315-preS2Ab-mediated preS2Ab. A: ELISA results show that the expression levels of the preS2Ab increase in the supernatants of Ad315-preS2Ab-infected L02 cells with increases in MOI; B: Western blotting shows that the expression of preS2Ab is high at an MOI of 100 pfu/cell. GAPDH is used as the loading control; C: The expressed preS2Ab in the supernatant of Ad315-preS2Ab-infected L02 cells recognizes liver cells from HBV transgenic Imprinting Control Region (ICR) mice as shown by a strong immunofluorescent reaction (left). Liver cells of normal ICR mice do not show labeling (right) (× 200). ELISA: Enzyme linked immunosorbent assay; HBV: Hepatitis B virus; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; MOI: Multiplicity of infection.

Figure 2 Inhibitory effects of the Ad315-preS2Ab-mediated preS2Ab against hepatitis B virus infection. ELISA results show HBsAg secretion in the supernatants of L02 cells infected with Ad315-preS2Ab. The inhibition of HBV infections increases with increasing Ad315-preS2Ab MOIs, as shown by decreases in HBsAg (P < 0.05). Cells infected with the Ad315 blank vector show no inhibitory effects against HBV infection. ELISA: Enzyme linked immunosorbent assay; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; MOI: Multiplicity of infection.

Figure 3 Ad315-preS2Ab effectively inhibited diethylnitrosamine-induced hepatic cirrhosis and carcinogenesis in hepatitis B virus transgenic mice. A: Ad315-preS2Ab-mediated preS2Ab expression demonstrates significant inhibitory effects against diethylnitrosamine-induced hepatic cirrhosis and carcinogenesis in HBV transgenic mice, as shown by significantly fewer (left panel) and smaller cancerous nodes (right panel) (P < 0.05); B: Pathological findings show that animals in the Ad315-preS2Ab group have a lesser degree of cirrhosis (upper panel, HE, × 100; arrows: proliferated fibrous septa) as well as fewer and smaller cancerous nodes (lower panel, HE, ×100; arrows: cancerous nodes) compared with the two control groups. HBV: Hepatitis B virus; HE: Hematoxylin and eosin. DEN: Diethylnitrosamine.